Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2005-05-10 | DANIEL R. OMSTEAD, PH.D.* (51), 30 ROWES WHARF, BOSTON, MA 02110 President of HQH and of HQL (since 2001); Trustee of HQH and of HQL (since 2003); ... * Trustee considered to be an "interested person" ... COMPENSATION TABLE ... Daniel R. Omstead, Ph.D. $0. |
| 2006-05-08 | Daniel R. Omstead, Ph.D. (52), President of HQH and of HQL (since 2001); Trustee of HQH and of HQL (since 2003)... Compensation Table: $0 total compensation. |
| 2007-05-10 | Daniel R. Omstead, Ph.D. (53), 30 Rowes Wharf, Boston, MA 02110 President of HQH and of HQL (since 2001); Trustee of HQH and of HQL (since 2003), President, Chief Executive Officer and Managing Member (since July 2002) of Hambrecht & Quist Capital Management LLC; President and Chief Executive Officer (2001-June 2002) and Managing Director (2000-June 2002) of Hambrecht & Quist Capital Management, Inc.; Director (since 2003) of Concentric Medical, Inc.; and Magellan Biosciences (since 2006). |
| 2008-05-05 | Daniel R. Omstead, Ph.D. (54), President of HQH and HQL; Interested Trustee; Total Compensation from both Funds and Fund Complex Paid to Trustees: $0. |
| 2009-05-01 | Daniel R. Omstead, Ph.D. (55), President of HQH and HQL; Interested Trustee; Compensation: $0 from both Funds. |
| 2010-04-27 | Daniel R. Omstead, Ph.D. (56), President, HQH and HQL; Interested Trustee; Compensation: $0 from both Funds. |
| 2011-06-08 | Dr. Omstead is President and Chief Executive Officer of Hambrecht & Quist Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH and HQL. Dr. Omstead is also President of HQL and HQH. ... Compensation Table ... Daniel R. Omstead, Ph.D. ... Total Compensation ... $0 |
| 2012-04-30 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Hambrecht & Quist Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH and HQL. Dr. Omstead is also President of HQL and HQH. Dr. Omstead is portfolio manager for the public and restricted/venture portfolios within HQH and HQL. |
| 2013-04-25 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH and HQL. Dr. Omstead is also President of HQH and HQL and serves on their Valuation Committee. ... Compensation Table For the fiscal year ended September 30, 2012 ... Daniel R. Omstead, Ph.D. $0 total compensation. |
| 2014-04-30 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH and HQL. Dr. Omstead is also President of HQH and HQL and serves on their Valuation Committee. ... Compensation Table ... Daniel R. Omstead, Ph.D. ... Total Compensation ... $0. |
| 2015-04-20 | Daniel R. Omstead, Ph.D.* (61) 100 Federal Street, 19th Floor, Boston, MA 02110 Trustee, HQH, HQL and THQ; President, HQH and HQL (since 2001); President, THQ (since 2014); Member of each Fund's Valuation Committee. Compensation Table: Total Compensation from All Funds in Fund Complex Paid to Trustees $0. |
| 2016-04-18 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH, HQL, THQ and THW. Dr. Omstead is also President of HQH, HQL, THQ and THW and serves on their Valuation Committee. |
| 2017-04-18 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to the Funds. Dr. Omstead is also President of the Funds and serves on their Valuation Committee. ... Compensation Table ... Daniel R. Omstead, Ph.D. ... Total Compensation from All Funds in Fund Complex Paid to Trustees $0. |
| 2018-04-18 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to the Funds. Dr. Omstead is also President of the Funds and serves on their Valuation Committee. Dr. Omstead is portfolio manager for the public and restricted/venture portfolios within the Funds. |
| 2020-04-14 | Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to the Funds. ... Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies. ... Dr. Omstead holds Ph.D. and Master's Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University. ... For the fiscal year ended September 30, 2019, the Independent Trustees as a group received $515 from HQH, $238 from HQL, $450 from THQ and $234 from THW for reimbursed expenses. ... Daniel R. Omstead, Ph.D. total compensation $0. |
| 2021-04-13 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC... He serves on their Valuation Committee. Compensation Table shows Daniel R. Omstead total compensation from all funds as $0. |
| 2022-04-12 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC and President of the Funds. He serves on their Valuation Committee. For the fiscal year ended September 30, 2021, his total compensation from the Funds was $0. |
| 2023-04-11 | Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC, a registered investment adviser that serves as investment adviser to the Funds. Dr. Omstead is also President of the Funds and serves on their Valuation Committee. For the fiscal year ended September 30, 2022, the Independent Trustees as a group received $2,098 from HQH, $2,037 from THQ and $1,140 from THW for reimbursed expenses. The following table sets forth information regarding compensation of the Trustees and Executive Officer by each Fund for the fiscal year ended September 30, 2022... Daniel R. Omstead, Ph.D. $0 total compensation. |
| Filing Date | Source Excerpt |
|---|---|
| 2005-05-10 | DANIEL R. OMSTEAD, PH.D.* (51), 30 ROWES WHARF, BOSTON, MA 02110 President of HQH and of HQL (since 2001); Trustee of HQH and of HQL (since 2003), President, Chief Executive Officer and Managing Member (since July 2002) of Hambrecht & Quist Capital Management LLC; President and Chief Executive Officer (2001-June 2002) and Managing Director (2000-June 2002) of Hambrecht & Quist Capital Management, Inc.; President and Chief Executive Officer (from 1998-2000) of Reprogenesis, Inc. For the fiscal year ended September 30, 2004 each Fund paid its Independent Trustees an annual fee of $20,000. Each Fund currently pays each Independent Trustee $500 for each Board and Committee meeting attended in person and $250 for each Board and Committee meeting attended by telephone. For the fiscal year ended September 30, 2004 Independent Trustees of each Fund were paid $1,000 for each Board and Committee meeting attended in person and $500 for each Board and Committee meeting attended by telephone. Currently, the Chairman of the Board of Trustees, the Chairman of the Audit Committee and the Chairman of the Valuation Committee of each Fund receives an additional annual fee of $2,500. Currently, the Chairman of the Nominating Committee and the Chairman of the Governance Committee of each Fund receives an additional fee of $1,500. During the fiscal year ended September 30, 2004 the Chairman of each Committee received an additional fee of $1,500. Independent Trustees are also reimbursed for travel expenses incurred in connection with attending such meetings. For the fiscal year ended September 30, 2004, the Independent Trustees as a group received $169,608 from HQH and $167,490 from HQL for fees and reimbursed expenses. Neither of the Funds directly paid any additional compensation to the Trustees for the fiscal year ended September 30, 2004. Neither of the Funds directly paid any compensation to any officer in excess of $60,000 for the fiscal year ended September 30, 2004. Trustees and officers of the Funds who hold positions with the Adviser receive indirect compensation from the Funds in the form of the investment advisory fee paid to the Adviser. The following table sets forth information regarding compensation of Trustees by the Funds for the fiscal year ended September 30, 2004, but does not include expenses. COMPENSATION TABLE For the fiscal year ended September 30, 2004 NAME OF TRUSTEE FROM EACH FUND TOTAL COMPENSATION FROM BOTH FUNDS AND FUND COMPLEX Daniel R. Omstead, Ph.D. $0 $0 |
| 2006-05-08 | Daniel R. Omstead, Ph.D. (52), President of HQH and of HQL (since 2001); Trustee of HQH and of HQL (since 2003), President, Chief Executive Officer and Managing Member of Hambrecht & Quist Capital Management LLC... Compensation Table: Daniel R. Omstead, Ph.D. $0 total compensation. |
| 2007-05-10 | Daniel R. Omstead, Ph.D. (53), 30 Rowes Wharf, Boston, MA 02110 President of HQH and of HQL (since 2001); Trustee of HQH and of HQL (since 2003), President, Chief Executive Officer and Managing Member (since July 2002) of Hambrecht & Quist Capital Management LLC; President and Chief Executive Officer (2001-June 2002) and Managing Director (2000-June 2002) of Hambrecht & Quist Capital Management, Inc.; Director (since 2003) of Concentric Medical, Inc.; and Magellan Biosciences (since 2006). Trustee considered to be an "interested person" within the meaning of the Investment Company Act of 1940, as amended (the "1940 Act"), through position or affiliation with Hambrecht & Quist Capital Management LLC (the "Adviser"). |
| 2008-05-05 | Daniel R. Omstead, Ph.D. (54), President of HQH and HQL; Interested Trustee; Total Compensation from both Funds and Fund Complex Paid to Trustees: $0. |
| 2009-05-01 | Daniel R. Omstead, Ph.D. (55), President of HQH and HQL; Trustee of HQH and HQL; Interested Trustee; Compensation: $0 from both Funds. |
| 2010-04-27 | Daniel R. Omstead, Ph.D. (56), Interested Trustee, President, HQH and HQL; No committee memberships mentioned; Compensation: $0 total from both Funds. |
| 2011-03-30 | Daniel R. Omstead Ph.D serves as President and Chief Executive Officer of the Adviser. The address for Dr. Omstead is c/o the Adviser at 2 Liberty Square, 9th Floor, Boston, MA 02109. |
| 2011-06-08 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Hambrecht & Quist Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH and HQL. Dr. Omstead is also President of HQL and HQH. |
| 2012-04-30 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Hambrecht & Quist Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH and HQL. Dr. Omstead is also President of HQL and HQH. Dr. Omstead is portfolio manager for the public and restricted/venture portfolios within HQH and HQL. As part of these responsibilities, Dr. Omstead is a member of the Board of Directors of several portfolio companies including Magellan Diagnostics, Dynex Corporation, Tibion Corporation, Celladon Corporation and Palyon Medical. |
| 2013-04-25 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH and HQL. Dr. Omstead is also President of HQH and HQL and serves on their Valuation Committee. ... Compensation Table ... Daniel R. Omstead, Ph.D. ... Total Compensation from both Funds in Fund Complex Paid to Trustees $0. |
| 2014-04-30 | Daniel R. Omstead, Ph.D.* (60) 2 Liberty Square, 9th Floor, Boston, MA 02109 Trustee, HQH and HQL; President, HQH and HQL (since 2001); Member of each Fund's Valuation Committee. ... For the fiscal year ended September 30, 2013 ... Daniel R. Omstead, Ph.D. ... Total Compensation from both Funds in Fund Complex Paid to Trustees $0. |
| 2015-04-20 | Daniel R. Omstead, Ph.D.* (61) 100 Federal Street, 19th Floor, Boston, MA 02110 Trustee, HQH, HQL and THQ; President, HQH and HQL (since 2001); President, THQ (since 2014); Member of each Fund's Valuation Committee. Compensation: $0 |
| 2016-04-18 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to HQH, HQL, THQ and THW. Dr. Omstead is also President of HQH, HQL, THQ and THW and serves on their Valuation Committee. Dr. Omstead is portfolio manager for the public and restricted/venture portfolios within HQH, HQL, THQ and THW. As part of these responsibilities, Dr. Omstead is a member of the Board of Directors of several portfolio companies including Dynex Corporation, EBI Life Sciences, Inc., Euthymics Biosciences, Inc., GenomDx Biosciences Inc., IlluminOss Medical, Inc., Insightra Medical, Inc., Neurovance, Inc. and Veniti, Inc. Dr. Omstead is also an observer of the Board of Directors of AlterG, Inc. Prior to joining the Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck & Co., Inc. Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies. Dr. Omstead holds Ph.D. and Master's Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University. He is an emeritus member of the Board of Directors of a non-profit agency that provides emergency shelter, housing and supportive services to homeless and low-income individuals and families in the Boston area. Dr. Omstead is also an Overseer at the Joslin Diabetes Center. Daniel R. Omstead, Ph.D. (62) 100 Federal Street, 19th Floor, Boston, MA 02110: Trustee, HQH, HQL, THQ and THW; President, HQH and HQL (since 2001); President THQ (since 2014); President THW (since 2015); Member of each Fund's Valuation Committee. Compensation: $0. |
| 2017-04-18 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to the Fund. Dr. Omstead is also President of the Fund and serves on its Valuation Committee. Dr. Omstead is portfolio manager for the public and restricted/venture portfolios within the Fund. As part of these responsibilities, Dr. Omstead is a member of the Board of Directors of several portfolio companies including EBI Life Sciences, Inc., Euthymics Biosciences, Inc., GenomDx Biosciences Inc., IlluminOss Medical, Inc. and Veniti, Inc. Dr. Omstead is also an observer of the Board of Directors of AlterG, Inc. Prior to joining the Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck & Co., Inc. Dr. Omstead provides the Fund with insights into both pharmaceutical and biotech companies. Dr. Omstead holds Ph.D. and Master's Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University. He is an emeritus member of the Board of Directors of a non-profit agency that provides emergency shelter, housing and supportive services to homeless and low-income individuals and families in the Boston area. Dr. Omstead is also a member of the Board of Trustees at the Joslin Diabetes Center. |
| 2018-04-18 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC, President of the Fund and serves on its Valuation Committee. Compensation Table: Daniel R. Omstead, Ph.D. $0. |
| 2020-04-14 | Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to the Funds. ... Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies. ... Dr. Omstead holds Ph.D. and Master's Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University. ... Dr. Omstead is President since 2001, Trustee HQH and HQL since 2003; THQ since 2014; THW since 2015. ... Dr. Omstead total compensation $0. |
| 2021-04-13 | Daniel R. Omstead, Ph.D.: Dr. Omstead is President and CEO of Tekla Capital Management LLC and President of the Funds. He serves on the Valuation Committee. For the fiscal year ended September 30, 2020, Dr. Omstead received no direct compensation from the Funds. |
| 2022-04-12 | Dr. Omstead is President and CEO of the Adviser and President of the Fund. He serves on the Valuation Committee. Compensation Table shows no compensation from the Fund. |
| 2023-04-11 | Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC and President of the Fund. He serves on the Valuation Committee. Compensation Table shows total compensation from the Fund is $0. |
Data sourced from SEC filings. Last updated: 2026-02-03